FDA Approves Eli Lilly COVID-19 Drug Without Remdesivir

FDA Approves Eli Lilly COVID-19 Drug Without Remdesivir

Expanding on their emergency authorization from November, the FDA has granted Eli Lilly approval for the use of their COVID-19 drug baricitinib to be taken on its own and not in combination with Gilead’s drug remdesivir for patients with COVID-19. With the...
FDA Grants Second Approval for Gilead’s Trodelvy

FDA Grants Second Approval for Gilead’s Trodelvy

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Trodelvy, a drug therapy for patients with locally advanced or metastatic urothelial cancer (mUC), an aggressive disease with a survival rate of 5.5%. Previously, Trodelvy was granted...
Gilead Sets Price for Covid Treatment Remdesivir

Gilead Sets Price for Covid Treatment Remdesivir

Gilead Sciences, the biotech company based out of California that created one of the first original treatments for Covid, has set the price for remdesivir between $2,340 and $3,120 for a typical course treatment. While remdesivir has still yet to prove to reduce...